BEMPETOL Tablet is an innovative lipid-lowering medication that contains Bempedoic Acid, a first-in-class ATP citrate lyase (ACL) inhibitor. It is primarily prescribed to lower low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia or mixed dyslipidemia, particularly in those who are intolerant to statins or require additional LDL-C reduction despite maximum tolerated statin therapy. By targeting cholesterol biosynthesis upstream of the HMG-CoA reductase pathway, BEMPETOL Tablet offers a novel and complementary mechanism to statins with a favorable safety profile. Manufactured under WHO-GMP-certified facilities, BEMPETOL Tablet represents a significant advancement in the management of cardiovascular risk associated with dyslipidemia.

This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.

BEMPETOL Tablet is an oral pharmaceutical formulation containing Bempedoic Acid, a non-statin lipid-lowering agent approved for use in the treatment of hypercholesterolemia and mixed dyslipidemia. As a first-in-class inhibitor of adenosine triphosphate citrate lyase (ACL), Bempedoic Acid works upstream in the cholesterol biosynthesis pathway and serves as an adjunct or alternative to statin therapy in patients requiring intensive LDL-C reduction. BEMPETOL Tablet is particularly beneficial for individuals who are statin-intolerant, have familial hypercholesterolemia, or fail to achieve optimal lipid control on statin monotherapy.

Bempedoic Acid exerts its therapeutic effect by inhibiting ACL, an enzyme involved in the conversion of citrate to acetyl-CoA, a critical precursor for cholesterol synthesis in the liver. By interrupting this step, the drug effectively decreases intracellular cholesterol levels, leading to upregulation of hepatic LDL receptors and increased clearance of LDL-C from the bloodstream. Unlike statins, Bempedoic Acid is a prodrug activated only in the liver and not in skeletal muscle tissue, thereby minimizing the risk of statin-associated muscle-related side effects such as myalgia and myopathy.

BEMPETOL Tablet is clinically proven to reduce LDL-C levels by approximately 15% to 25% when used alone, and up to 38% when combined with statins or ezetimibe. The CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) clinical trial program has demonstrated its efficacy and safety in a wide spectrum of patients, including those with established atherosclerotic cardiovascular disease (ASCVD), heterozygous familial hypercholesterolemia (HeFH), and statin intolerance. In patients unable to tolerate high-dose statins, BEMPETOL serves as an effective alternative to achieve LDL-C targets recommended by international lipid guidelines.

The pharmacokinetics of Bempedoic Acid support once-daily dosing. It has a long plasma half-life of approximately 21 hours, is highly protein-bound, and undergoes hepatic metabolism. Since activation occurs via liver-specific enzymes (ACSVL1), the drug avoids accumulation in skeletal muscle tissue, reducing the incidence of muscle-related adverse effects. Bempedoic Acid does not inhibit or induce major cytochrome P450 isoenzymes, and hence has a low potential for drug-drug interactions. However, when co-administered with certain drugs like simvastatin or pravastatin, dose adjustments may be required.